Virometix has closed a $15 million financing round from its existing shareholders, marking a significant step forward for the Swiss biotechnology company as it accelerates the development of its fully synthetic vaccine pipeline. The investment will drive continued progress on V-212, the company’s lead serotype independent pneumococcal vaccine candidate now in Phase I clinical evaluation, while also supporting broader enhancements to its Synthetic Virus Like Particle platform.
The new capital will fund multiple initiatives tied to V-212’s advancement. The company expects topline results from the ongoing Phase I clinical trial in the first quarter of 2026. Preparations will also continue for a planned Phase Ib combination study evaluating V-212 in conjunction with an approved pneumococcal conjugate vaccine. Virometix will further complete OPK assay validation to generate immunogenicity and functional readouts, carry out upgrades to the SVLP technology platform, and progress next-generation pneumococcal vaccine programs toward preclinical development.
V-212 represents a new class of fully synthetic, serotype-independent vaccines designed to prevent Streptococcus pneumoniae infections. The candidate integrates multiple conserved antigenic epitopes from essential pneumococcal surface proteins conjugated to Virometix’s SVLP nanoparticles.
These nanoparticles contain built-in adjuvant components such as T helper epitopes and TLR ligands, eliminating reliance on biological carrier proteins and enabling a streamlined, entirely synthetic manufacturing process. In preclinical studies, V-212 generated strong and durable immune responses in animal models, demonstrated protection against lethal sepsis, and showed cross-reactivity with numerous pneumococcal serotypes, including those not covered by PCV 13.
The Phase I trial (NCT06975319) is a randomized, double blind, placebo-controlled, first-in-human study taking place at the Centre for Vaccinology at Ghent University Hospital. Sixty healthy adult volunteers between the ages of 18 and 45 have been enrolled, with initial safety and immunogenicity results expected in early 2026.
Virometix continues to expand its broader vaccine platform as it develops synthetic vaccines targeting infectious diseases and cancer. Its SVLP technology applies rational molecular design and chemical synthesis to rapidly create optimized candidates with improved safety, efficacy, scalability, and stability.
KEY QUOTE:
“This financing demonstrates the continued confidence and commitment of our investors to Virometix’s mission and platform. Our fully synthetic SVLP technology enables the design of broad-spectrum, self-adjuvanted vaccines with highly scalable manufacturing. With V-212 in clinical development, we are well positioned to deliver a truly next-generation approach to pneumococcal prevention.”
Anna Sumeray, Chief Executive Officer of Virometix
